OncView™ Podcast: Updates in Managing Extensive-Stage Small Cell Lung Cancer

Podcast

This special edition of the “Oncology Peer Review On-The-Go” dives into recent updates and important treatment strategies for extensive-stage SCLC management.

As part of its OncView™ video series, CancerNetwork® spoke with Benjamin Levy, MD, of the John Hopkins Sidney Kimmel Comprehensive Cancer Center, to discuss frontline management of extensive-stage small cell lung cancer (SCLC) and the recent updates in the field.

In the video series, Levy discussed the following:

To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast wherever you get your podcasts.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.